Sunday, October 15, 2023 8:55:37 PM
1019O - Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors
Background
ADP-A2M4CD8 is a TCR T-cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), modified with a CD8a coreceptor, to treat human leukocyte antigen A*02–eligible patients (pts) with unresectable/metastatic solid tumors. ADP-A2M4CD8 monotherapy has demonstrated an acceptable benefit-to-risk profile and encouraging anti-tumor activity in the ongoing phase 1 SURPASS trial. Nevertheless, inhibition of immunosuppressive pathways may improve anti-tumor responses; therefore, new SURPASS cohorts include ADP-A2M4CD8 combined with nivolumab or pembrolizumab. We report data from pts receiving monotherapy and nivolumab combination therapy.
Methods
T-cells are obtained by leukapheresis, transduced with a lentiviral vector carrying the TCR and CD8a coreceptor genes, expanded ex vivo, and infused back to the pt following lymphodepleting chemotherapy. ~Four weeks after ADP-A2M4CD8 infusion, a subset of pts also received nivolumab 480 mg every 4 weeks until unacceptable toxicity/disease progression. Primary and secondary objectives are safety and anti-tumor activity, respectively.
Results
As of March 9, 2023, 51 pts with a median age of 60 years (range: 31–75) mainly with melanoma, non-small cell lung, ovarian, gastroesophageal, head and neck, or urothelial cancers received 1.02–9.95x109 ADP-A2M4CD8 T-cells. Median (range) number of prior lines of therapy was 3 (1–8) and MAGE-A4 expression H-score was 250 (90–300). The four most common adverse events related to T-cell therapy were cytokine release syndrome (n=38 [74.5%]; 7 [13.7%] were Grade≥3), neutropenia (27.5%), pyrexia and fatigue (each 21.6%). Overall response rate per RECIST v1.1 by investigator review in monotherapy pts (n=45) was 35.6% (2 complete response, 14 partial response [PR]). Median duration of response was 20.79 weeks (95%CI: 11.6, 30.9). In pts assigned to nivolumab combination (n=6), there was 1 PR, 3 stable disease, and 2 not evaluable (2 pts have not received nivolumab and have no post-baseline RECIST assessment). Data from additional pts treated by August 2023 will be presented.
Conclusions
ADP-A2M4CD8 continues to show an acceptable benefit-to-risk profile, including in pts receiving nivolumab combination therapy.
Recent ADAP News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:13:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:07:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:31:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:46:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 12:13:01 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/30/2023 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:05:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 12:37:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 12:07:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/31/2023 09:19:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/10/2023 08:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:06:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 11:42:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2023 09:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2023 09:05:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM